Protection from Biothreats: DOD to Modernize Medical Countermeasures Development
The COVID-19 pandemic demonstrated the need to alter how the DoD conducts research, development and acquisition of medical countermeasure and ...
The COVID-19 pandemic demonstrated the need to alter how the DoD conducts research, development and acquisition of medical countermeasure and ...
Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats ENA Respiratory has been awarded ...
The U.S. Department of Health and Human Services (HHS) announced on Feb 10. it will acquire 600,000 treatment courses of ...
Dynavax Technologies Corporation and the U.S. Department of Defense (DOD) today announced an agreement for approximately $22 million over two and a half years to ...
Rigel Pharmaceuticals, Inc. announced on Jan. 29 it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program ...
The Department of Defense (DOD) awarded a $6 million agreement to Pulmotect, Inc., a clinical-stage biotechnology company, to execute two ...
Cue Health Inc. will receive an $481 Million contract from the Department of Defense (DOD), on behalf of the U.S. ...
During the upcoming flu season, public health and medical professionals will require diagnostic tools to determine if a patient with ...
The Department of Defense (DOD) awarded $125 million to Goldbelt Security, LLC on Aug. 31, 2020 to procure 530 million ...
Bavarian Nordic A/S announced today topline results from the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against three ...
A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership announced Apr. 1 ...
Scientists from Noblis and the Defense Biological Product Assurance Office (DBPAO), a component of the Joint Program Executive Office for ...
Nerve agents are the most toxic of the known chemical agents. They are hazards in both liquid and vapor states ...
Today, the U.S. Food and Drug Administration and the Department of Defense’s (DoD) Office of Health Affairs signed a Memorandum ...
The Joint Program Executive Office for Chemical and Biological Defense is seeking information on the capabilities of organizations to develop ...
An innovative approach is being initiated by the Department of Defense, which will accelerate MCM delivery by leveraging platform technologies ...
Therapeutic pharmaceuticals against chemical, biological, radiological and nuclear (CBRN) warfare agents are required to support the Joint Forces across a ...
No definitive diagnostic test exists for Burkholderia, a category B agent caused by Burkholderia pseudomallei bacterium, which poses a threat ...
The Enhanced Maritime Biological Detection (EMBD) program is charged with finalizing development, and complete testing, integration and production of an ...
The Defense Biological Product Assurance Office (DBPAO), previously known as the Critical Reagents Program (CRP), is conducting market research on ...